old agglutinins have been one of the banes of blood group serologists since pretransfusion testing protocols were first implemented. Cold autoagglutinins interfere with ABO/Rh typing tests, yield unwanted positive tests for unexpected antibodies, and may mask the presence of concomitant, clinically significant alloantibodies. Cold alloagglutinins, such as anti-M, -P 1 , or -Le a rarely cause accelerated destruction of mismatched red blood cells (RBCs), and it is not necessary to detect examples of these antibodies that only react below body temperatures.
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The extent to which cold agglutinins can interfere with the results of pretransfusion antibody detection and compatibility tests is evident from a study by Garratty 1 on the importance of anticomplement reagents in immunohematology. With a low-ionic-strength saline (LISS) method that included room temperature incubation and polyspecific (anti-IgG+ C3) antiglobulin serum, the rate of unwanted positive tests (due primarily to the detection of cold-reactive auto-and alloagglutinins) was on the order of 1.41 percent! Omitting the room temperature incubation phase and use of anti-IgG reduced the unwanted positive rate reduced to 0.1 percent.
AVOIDING COLD AGGLUTININS
Given these introductory comments, the proper handling of cold agglutinins in the transfusion service requires that pretransfusion antibody screening be performed utilizing methods that avoid their detection, namely: In these regards, polyethylene glycol or gel techniques 2, 3 are ideal methods to use. Data supporting safety of the above recommendations are found in Trudeau and colleagues, 4 Laferriere and coworkers, 5 Judd and colleagues, [6] [7] [8] and Judd.
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The one problem that can arise from omitting readings for direct agglutination when screening for unexpected antibodies is the occurrence of a positive immediate-spin cross-match when the screening tests are negative. In this situation, before implementing an electronic cross-match, our approach was to verify that blood of the correct ABO type had been selected and to crossmatch the units by the indirect anitglobulin test (IAT). If the units were compatible by IAT, they were released for transfusion. If not, an antibody identification study was initiated. Their inappropriate management entails application of prewarmed tests (see Judd, 10,11 Judd et al., 12 Leger and Garratty 13 for an in-depth discussion).
LABORATORY MANAGEMENT OF COLD AGGLUTININS
SELECTING BLOOD FOR TRANSFUSION
Having differentiated alloagglutinins from autoagglutinins and ruled out the presence of underlying, potentially significant alloantibodies, the following policies can be helpful in the selection of blood for transfusion:
Alloanti-M, -P 1 , and -Le and anti-HI (active at IAT) 
Alloanti-I, -P, and so forth
Never prewarm! These antibodies have the potential to cause accelerated destruction of mismatched RBCs. 20, 21 They should be managed in the same way as any potentially significant antibody to a high-prevalence antigen.
Cold agglutinins and heart surgery
There are conflicting opinions expressed in surgical journals. [22] [23] [24] Our approach is "don't screen for them; don't report them." We discourage requests for titration and thermal amplitude tests and recommend use of room temperature crystalloid instead of cold cardioplegia.
SUMMARY
In summary, although cold agglutinins can and have been a challenging, and perhaps even an annoying, phenomenon, the strategies described above can limit their effect on the transfusion service while helping to ensure maximal transfusion safety. Still, of greatest importance is the need to differentiate cold autoantibodies from cold alloantibodies and to exclude the presence of concomitant IgG alloantibodies.
